| [1] |
Liu FY, Wang MQ, Duan F, et al. Hepatic artery chemoembolization in patients with liver metastasis from pancreatic carcinoma[J]. Zhongguo Zhong Liu Lin Chuang, 2012, 39(6): 331-5. [刘凤 永,王茂强,段峰,等. 胰腺癌肝转移的介入治疗[J].中国肿瘤临 床,2012,39(6):331-5.]
|
| [2] |
Katopodis O, Souglakos J, Stathopoulos E, et al. Frontline treatment with gemcitabine, oxaliplatin and erlotinib for the treatment of advanced or metastatic pancreatic cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG) [J]. Cancer Chemother Pharmacol, 2014, 74(2):333-40.
|
| [3] |
Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges [J]. Nat Rev Clin Oncol, 2010, 7( 3):163-72.
|
| [4] |
Tas F, Sen F, Keskin S, et al. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival [J]. Mol Clin Oncol, 2013(1):788-92.
|
| [5] |
Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancer[J]. J Clin Gastroenterol, 2008, 42 (1):86-91.
|
| [6] |
Liu LX, Ji W, Wang JH, et al. A retrospective analysis on survival factors of transarterial chemoembolization for patients of pancreatic carcinoma with liver metastasis [J]. Fu Dan Xue Bao(Yi Xue Ban), 2011, 38(2): 101-6.[刘凌晓, 姬巍, 王建华, 等. 胰腺癌肝转移患者综合性介入栓塞治疗生存情况的回顾性分 析[J] 复旦学报（医学报）, 2011, 38(2):101-6.]
|
| [7] |
Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase i/ii trial [J]. J Clin Oncol, 2011, 29(34): 45 49-50.
|
| [8] |
Ouyang HQ, Huang JQ, Liu LM, et al. Clinical analysis of multimodality treatment for 164 cases of pancreatic cancer with liver metastases[C].The First TCM and Western Medicine Oncology Forum in 2009 by Doctors and Young and Middle-aged Clinicians, 2011: 211-3.[欧阳华强,黄建琴,刘鲁明,等.多学科综 合治疗胰腺癌肝转164例临床分析[C].2009年首届全国中西医 肿瘤博士及中青年医师论坛, 2011: 211-3.]
|
| [9] |
Zhao J, Hu Y, Liao Q, et al. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer[J]. World J Gastroenterol, 2014, 20(19): 5875-80.
|
| [10] |
Yang GY, Malik NK, Chandrasekhar R, et al. Change in CA 19-9 levels after chemoradiotherapy predicts survival in patients with locally advanced unresectable pancreatic cancer [J]. J Gastrointest Oncol, 2013, 4(4): 361-9.
|
| [11] |
Ni QX, Yu XR, Liu L. Discussion for the clinical definition of pancreatic cancer in China [J]. Zhongguo Ai Zheng Za Zhi, 2012, 22 (2):81-7.[倪泉兴, 虞先溶, 刘亮. 中国胰腺癌临床诊断标准的 探讨[J] 中国癌症杂志, 2012, 22(2): 81-7.]
|
| [12] |
Shrikhande SV, Kleeff J, Reiser C, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma [J]. Ann Surg Oncol, 2007, 14 (1): 118-27.
|
| [13] |
Lorente-Herce JM, Parra-Membrives P, Díaz-Gómez D. Increased survival after resection of pancreatic cancer liver metastases[J]. Cir Esp, 2013, 91(6): 390-2.
|
| [14] |
SK S, Burkert B, AM C, et al. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy [J]. HPB Surg, 2010, 2010: 579672.
|
| [15] |
Azizi A, Naguib NN, Mbalisike E, et al. Liver metastases of pancreatic cancer : role of repeti tive transar ter ial chemoembolization (TACE) on tumor response and survival [J]. Pancreas, 2011, 40(8): 1271-5.
|
| [16] |
Klimant E, Markman M, Albu DM. Clinically meaningful response to sequential gemcitabine-based chemotherapy regimens in a patient with metastatic pancreatic cancer [J]. Case Rep Oncol, 20 13, 6(1): 72-7.
|
| [17] |
Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer [J]. N Engl J Med, 20 11, 364(19): 1817-25.
|
| [18] |
Sung HY, Jung SE, Cho SH, et al. Long-term outcome of highintensity focused ultrasound in advanced pancreatic cancer [J]. Pancreas, 2011, 40(7): 1080-6.
|
| [19] |
De Jong MC, Farmell MB, Sclabs G, et al. Liver-directed therapy for hepatic metastases in patients undergoing pancreaticoduodenectomy: a dual-center analysis [J]. Ann Surg, 20 10, 252(1):142-8.
|
| [20] |
Xia SA, Wang J, Che LP, et al. Clinical significance of threedimensional conformal technique treatment for locally advanced pancreatic cancer[J].Zhongguo Yi Yao Dao Bao, 2012, 9( 35):75-6,80.[夏士安, 王佳, 车莉萍, 等. 探讨三维适行放射治 疗在晚期胰腺癌中的临床意义[J]. 中国医药导报, 2012, 9(35): 75 -6,80.]
|
| [21] |
Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma. The Mayo Clinic experience(1975-2005) [J]. J Clin Oncol, 2008, 26 (21) : 3511-6.
|
下载:
